TP53 rs1042522 polymorphism has been associated with increased risk of various cancers, including breast cancer, prostate cancer, thyroid cancer, transitional cell carcinoma and chronic myeloid leukemia (Huang et al., 2003; Gemignani et al., 2004; Wu et al., 2004; Granja et al., 2004; Kuroda et al., 2003; Bergamaschi et al., 2004). This evidence concerns the gene TP53 and transitional cell carcinoma.